Skip to main content
Account

Peer review reports

From: Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries

Original Submission
25 Nov 2021 Submitted Original manuscript
10 Jan 2022 Reviewed Reviewer Report - Andrew Lofts Gray
27 Feb 2022 Reviewed Reviewer Report
6 Jun 2022 Author responded Author comments - Hyun Kyeong Yoo
Resubmission - Version 2
6 Jun 2022 Submitted Manuscript version 2
10 Jun 2022 Reviewed Reviewer Report
12 Jun 2022 Reviewed Reviewer Report - Andrew Lofts Gray
5 Aug 2022 Author responded Author comments - Hyun Kyeong Yoo
Resubmission - Version 3
5 Aug 2022 Submitted Manuscript version 3
26 Aug 2022 Reviewed Reviewer Report - Andrew Lofts Gray
12 Oct 2022 Author responded Author comments - Hyun Kyeong Yoo
Resubmission - Version 4
12 Oct 2022 Submitted Manuscript version 4
Publishing
16 Oct 2022 Editorially accepted
4 Nov 2022 Article published 10.1186/s12913-022-08683-y

Learn about peer review

Back to article page

Navigation